Pharmacy Medical News about Neutropenic Fever

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem-Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever
Pharmacotherapy, 08/03/09

Arnold HM et al. – The alternative meropenem dosage of 500 mg every 6 hours yielded similar patient outcomes, including time to defervescence, need for additional antibiotics, duration of therapy, and mortality, when compared with the traditional meropenem dosage and imipenem–cilastatin in adults with febrile neutropenia. In addition, no adverse effects on clinical outcomes were observed with the alternative dosage of meropenem.

<< Previous
Assessment of a Point-of-Care Metabolic Risk Screening Program in...

Next >>
Governance in non-for-profit hospitals: Effects of board members...

Predicting the complicated neutropenic fever in the emergency department
Emergency Medicine Journal, 11/06/09 Relevance Score: 66%

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever
Journal of Medical Microbiology, 10/21/09 Relevance Score: 64%

Management of fever in children: Summary of the Italian pediatric society guidelines
Clinical Therapeutics, 10/19/09 Relevance Score: 45%

Periodic fever responds to vitamin B12 treatment
Rheumatology International, 10/02/09 Relevance Score: 45%

Differentiating PFAPA Syndrome From Monogenic Periodic Fevers
Pediatrics, 10/01/09 Relevance Score: 45%